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Once a product for an ORD is approved; conditional or
non conditional, there are still unanswered questions on
long-term safety and effectiveness. And there is often
limited knowledge on natural progression of the disease
and optimal disease management. These questions could
be answered by prospectively collecting real world data
into patient registries.
T h es c o p eo ft h er e g i s t r ys h o u l db ei nl i n ew i t h
demands from registry stakeholders such as regulatory
agencies, payers, patients, treating physicians and the
pharmaceutical industry.
Fabry and Hunter Outcome Surveys (FOS and HOS)
supported by Shire Human Genetic Therapies have
been designed and managed for almost 10 years in close
collaboration with stakeholders.
Patient registries do meet challenges related to data
completeness and quality. Treating physicians are not
mandated to provide real world data to patient
registries.
Over the years, global guidance on good practices for
design, conduct, analysis and reporting of patient regis-
try data have been developed to increase the quality and
facilitate the usage of patient registry data. In addition,
specific initiatives from FOS and HOS Governance
bodies have been undertaken to increase the robustness
of the collected data.
FOS and HOS have contributed to increased disease
knowledge and improved disease management. Exam-
ples on findings are increased knowledge of the natural
progression of the diseases, disease involvement in
patient populations not eligible for inclusion into the
initial clinical trials as well as long term clinical benefit
of treatment.
However there are still questions to be addressed and
answered especially to support pricing and reimburse-
ment decisions in some European countries. This is to
insure patients gets access to equal treatment on
approved treatment independent of where they live in
Europe.
Questions that need to be more closely addressed and
evaluated are beyond clinical effectiveness and related to
patients capacity to work and implications on public
spending for these ORD.
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